What do systematic reviews say?

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).

• Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
  HR 0.77 [0.68, 0.87]
  3 studies · 2261 participants
  Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).

• Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
  RR 2.98 [2.19, 4.04]
  1 study · 375 participants
  Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower prostate cancer‐specific death5 compared with ADT only (moderate certainty).

• Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
  RR 0.79 [0.7, 0.89]
  3 studies · 2261 participants
  Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).

• Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
  HR 0.63 [0.56, 0.71]
  3 studies · 2261 participants
  Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).

• Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
  RR 79.41 [4.92, 1282.78]
  1 study · 385 participants
  Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher all adverse events compared with ADT only (low certainty).

• Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
  RR 1.11 [1.06, 1.17]
  1 study · 375 participants
  Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

• Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 790 participants
  Low